Termination by Pfizer. Notwithstanding anything contained herein to the contrary, Pfizer shall have the right to terminate this Agreement, either in its entirety or in relation to any Target and relevant Compounds and Products under this Agreement, at any time for any or no reason in its sole discretion by giving sixty (60) days’ advance written notice to Arvinas.
Termination by Pfizer. Pfizer shall have the right to terminate this Agreement under this Section 8.02(a) upon written notice to Customer if Customer breaches any material obligation hereunder, including without limitation failing to pay any amount due hereunder which is not subject to a bona fide dispute when due hereunder (as described in the last two (2) sentences of Section 4.02(b) hereof), within the time required for such payment and such payment default is not cured within [***] after the receipt of written notice to Customer specifying such payment default, and such other default is not cured within [***] after receipt of written notice to Customer specifying such other default. During the initial Term or any Extension Period, Pfizer shall have the right in its sole discretion to terminate this Agreement upon [***] prior written notice to Customer without cause.
Termination by Pfizer. Pfizer shall have the right to terminate the license granted to Medarex under Section 2.1.1 and its associated obligations if and only if Medarex or its Affiliates or Sublicensees/Licensees materially breaches (a) this Agreement, (b) Section 2.1, 2.2 or 2.3 of the Xxxxxxx License Agreement, or (c) Section 3.1 of the Xxxxxxx License Agreement (solely where such breach has a material adverse effect on Pfizer’s ability to Exploit Pfizer Products under the Licensed Patents (as defined in the Xxxxxxx License Agreement), and Medarex or its Affiliates or its Sublicensees/Licensees fails to cure such breach (under clause (a), (b) or (c) of this Section 2.5.3) within thirty (30) days after written notice from Pfizer specifying the nature of such breach. Pfizer shall have the right to terminate the license granted to it under Section 2.1.2, and its associated rights, in whole or as to any portion of the Medarex Patents on written notice to Medarex.
Termination by Pfizer. Without limiting any other legal or equitable remedies that Pfizer may have, if this Agreement is terminated by Pfizer in accordance with Section 13.3 or if this Agreement is terminated in accordance with Section 13.2 and Auxilium is the breaching Party, then Pfizer shall have the option, in its sole discretion, to terminate this Agreement, in which case the provisions of Section 14.1 shall apply; provided, however, that such termination must be exercised within one hundred twenty (120) days after written notice of such breach by Pfizer to Auxilium pursuant to Section 13.2 or 13.3, as applicable.
Termination by Pfizer. If this Agreement is terminated by Pfizer pursuant to Section 10.2, the license granted by Archemix to Pfizer pursuant to Section 6.4 shall survive and the license granted by Archemix to Pfizer pursuant to Section 6.5 shall survive solely as applied to Products being commercialized by Pfizer as of the effective date of termination or derived from Early Leads and Optimized Leads being developed by Pfizer as of the effective date of termination, if any, in each case subject to Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. Pfizer’s continued payment of all milestone, Royalty and other payments under and in accordance with this Agreement with respect thereto.
Termination by Pfizer. After this Agreement has been in effect for a period of [********] months, during the next ensuring [******], Pfizer may by notice terminate this Agreement, with or without cause. If Pfizer terminates this Agreement pursuant to this Section, it will make a termination payment within [*****] days equal to the Funding Payments which would otherwise have been due for the [******] period from [******* ******] and will retain all rights and duties set forth in the License Agreement. If Pfizer does not elect to terminate this Agreement during the [ ***] period described in this Section, the Agreement will continue according to its terms until its termination date.
Termination by Pfizer. 9.1 Eighteen (18) months after the date of initiation of Pfizer Compound Production and occupancy of the Production Facility by Pfizer, Pfizer may terminate this Agreement, without cause, upon six (6) months' notice to ArQule, effective at the conclusion of the six-month notice period. If Pfizer does not provide ArQule notice at that time, Pfizer may only terminate the Agreement pursuant to Section 8.3.
Termination by Pfizer. 9.4.1 After this Agreement has been in effect for a period of eighteen (18) months, Pfizer may terminate this Agreement, with or without cause, with six (6) months notice to Microcide (such termination shall not be effective until twenty-four (24) months after the Effective Date). If Pfizer terminates this Agreement pursuant to this Section, it will make the payments which would otherwise have been due for such six (6) month 14 period; provided, however, that such termination shall not terminate Pfizer's right and obligations pursuant to the License Agreement.
Termination by Pfizer. Pfizer may terminate this Agreement: (A) upon 30 days prior written notice to Institution if: (i) the Protocol is materially modified in a way unacceptable to Pfizer, (ii) Study conduct is not completed within six months after the expected Study Completion date, (iii) the Study does not start within six months of the Effective Date, (iv) the Subject enrollment rate is significantly slower than outlined in the Protocol or needed to complete the Study by the Study Completion date; or (v) the Study design or objectives are no longer scientifically relevant or if Pfizer ceases production, commercialization or development of the Pfizer Product; or (B) immediately upon written notice to Institution if Principal Investigator becomes unavailable or withdraws from the Study and Pfizer and Institution are unable to agree upon a successor within 30 days after Pfizer is notified. 10.2.4.
Termination by Pfizer. (a) [ * ]. Prior to making the [ * ], above, PFIZER may terminate this Agreement because of a material adverse development related to the safety, efficacy, pulmonary delivery system efficiency, significant adverse change in the market for Products, the quality of the Products (“Adverse Development”) or, in its sole discretion, without cause (i.e., not because of an Adverse Development or default by INHALE). If PFIZER elects to terminate this Agreement [ * ] because of an Adverse Development or without cause PFIZER shall: (1) give INHALE [ * ] advance notice of such termination, (2) provide INHALE free-of-charge, with the Termination Documents (as defined below), which INHALE may use as INHALE sees fit and which INHALE may provide to a third party partner for use in continuing development of the Products and, (3) if terminated for reasons other than an Adverse Development or default by INHALE, [ * ], within thirty (30) days of giving INHALE notice, which [ * ]. For purposes of this Section 17.4 “
